Amgen’s Imdylltra Gains Conditional Approval in UK for Extensive-Stage Small Cell Lung Cancer
US biotech company Amgen (NASDAQ: AMGN) has received conditional approval from the UK’s Medicines and...
Amgen
Kexing Pharmaceutical Partners with Shandong Boan for Biosimilar Commercialization in Hong Kong and Macau
China-based Kexing Pharmaceutical (SHA: 688136) has entered into a commercialization cooperation agreement with fellow Chinese...
Mabwell Bioscience Secures Licensing Deal with TABUK Pharmaceutical for MENA Region
China-based Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has inked a licensing deal with TABUK...
Amgen’s Blincyto Meets Primary Endpoint in Phase III AALL1731 Study for Pediatric B-ALL
US-based biotechnology company Amgen (NASDAQ: AMGN) has published the results from the Phase III study...
Amgen Expands Biomanufacturing Footprint in North Carolina with Second Facility
US biotech company Amgen (NASDAQ: AMGN) has announced plans to construct a second drug substance...
Mabwell Bioscience Enters Licensing Agreement for Biosimilar Denosumab in Peru
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a licensing agreement with its...
AstraZeneca’s Tezspire Meets Phase III Co-Primary Endpoints in CRSwNP Study
AstraZeneca Inc., (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has announced positive high-level results...
Amgen’s Tavneos Receives NMPA Approval for ANCA-Associated Vasculitis Treatment in China
US biotechnology company Amgen (NASDAQ: AMGN) has announced that it has received market approval in...
Amgen Reports Q3 2024 Revenues of USD 8.5 Billion, Marking a 23% YOY Increase
US biotechnology company Amgen (NASDAQ: AMGN) has announced its financial results for the third quarter...
Shanghai Henlius and Organon Submit Biosimilar Application for Denosumab to FDA
Shanghai Henlius Biotech Inc. (HKG: 2696) and its US partner Organon (NYSE: OGN) have jointly...
FDA Extends Review of Amgen’s Lumakras for KRAS G12C mCRC Treatment to January 2025
On October 18, FirstWord reported that the U.S. FDA has extended the review period for...
MediLink Therapeutics Partners with Amgen for Clinical Trial in Small Cell Lung Cancer
Suzhou-based biotech MediLink Therapeutics (Suzhou) Co., Ltd has announced a partnership with US pharmaceutical giant...
Amgen’s Tepezza Receives Approval in Japan for Treating Thyroid Eye Disease
Amgen (NASDAQ: AMGN), a prominent biotechnology company based in the U.S., has announced that its...
Amgen to Establish New Site in Hyderabad, India, with Focus on Technology and Digital Innovation
Amgen (NASDAQ: AMGN), a leading biopharmaceutical company based in the U.S., has announced strategic plans...
Amgen Halts Development of Claudin 6-Targeting BiTE Immune Therapy AMG 794
Amgen Inc. (NASDAQ: AMGN), a leading biopharmaceutical company based in the U.S., has decided to...
Amgen Secures Commercialization Rights for Avacopan in Asia and Latin America
Amgen (NASDAQ: AMGN), a leading biopharmaceutical company, has entered into a licensing agreement with CSL...
Amgen’s Blincyto Secures New Indication Approval for B-ALL Consolidation Treatment in the US
Amgen (NASDAQ: AMGN) has announced that its bispecific T-cell engager (BiTE) Blincyto (blinatumomab) has received...
Amgen’s Prolia Secures NMPA Approval for Treating Glucocorticoid-Induced Osteoporosis in High-Risk Patients
Biopharmaceutical giant Amgen has received marketing approval from China’s National Medical Products Administration (NMPA) for...
Novartis Halts Development of KRAS Inhibitor Opnurasib Due to Competitive Market
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has reportedly halted the development of its Phase...
Amgen’s Bkemv Becomes First Biosimilar to Challenge AstraZeneca’s Soliris with FDA Approval
Amgen Inc. (NASDAQ: AMGN), a leading biopharmaceutical company, has been granted regulatory approval by the...